Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease
Yarrow is advancing YB-101—a potential first-in-class anti-TSHR antibody, designed to directly disrupt the central mechanism driving both Graves’ disease (“GD”) and thyroid eye disease (“TED”)
Dosing commenced in Phase 2a/2b GD trial following FDA Fast Track Designation, with Phase 2a data expected in 2H 2027
Data from ongoing Phase 1 multiple ascending dose (“MAD”) trial in patients with TED, conducted by partner, GenSci, in China expected in 2H 2027
Previously announced private financings totaling $200 million expected to fund operations into 2028
Shares of combined company common stock to trade on Nasdaq under ticker symbol “YARW”